Pay in 4 interest-free payments of $5.86 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
HCSC had it
GLP-1 Key Research Facts Full name: Glucagon-Like Peptide-1 incretin hormone of the proglucagon family Primary bioactive form: GLP-1(736)amide 30 amino acids, C-terminally amidated Gene source: Proglucagon gene processed by PCSK1 in intestinal L-cells and brainstem NTS neurons In vivo half-life: Approximately 12 minutes rapidly inactivated by DPP-4 (cleaves His7-Ala8 dipeptide) Primary receptor: GLP-1R (GLP-1 receptor) class B G protein-coupled receptor (GPCR) Signalling: GLP-1R activation cAMP elevation PKA/CREB activation glucose-dependent insulin secretion Additional signalling: PI3K/Akt pathway -cell survival, proliferation, and glucose sensitivity Secretion pattern: Biphasic post-meal release from intestinal L-cells early neural/endocrine peak + late direct nutrient-contact peak Fasting plasma level: ~510 pmol/L
Clinical observations have revealed improvements in blood sugar regulation, reductions in liver fat deposits, decreased inflammatory markers, and positive shifts in cardiovascular risk profiles
The reality of regain For patients coming off GLP-1 medications, the main expectation is straightforward: weight regain is common because obesity is a chronic condition
Ungar, PhD, a professor at Penn Engineering, notes that while clinical trials are excellent at flagging high-risk safety concerns, they often overlook the day-to-day symptoms that bother patients the most
US$ 24.69
US$ 28.73
US$ 28.01
US$ 22.61
US$ 27.98
US$ 21.06
US$ 25.53
US$ 26.21
US$ 21.86
US$ 23.74
